Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fennec Pharmaceuticals Inc
(NQ:
FENC
)
5.840
+0.140 (+2.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fennec Pharmaceuticals Inc
< Previous
1
2
3
Next >
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
August 13, 2024
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
3 Dirt-Cheap Stocks Under $10 That Could EXPLODE!
July 29, 2024
These dirt cheap stocks under $10 have the potential to rise rapidly and create fortunes for bold investors.
Via
InvestorPlace
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 14, 2024
Via
Benzinga
Fennec Pharmaceuticals's Earnings Outlook
March 20, 2024
Via
Benzinga
Earnings Scheduled For November 6, 2023
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
Preview: Fennec Pharmaceuticals's Earnings
November 03, 2023
Via
Benzinga
Analyst Ratings for Fennec Pharmaceuticals
June 21, 2023
Via
Benzinga
FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 14, 2024
FENC stock results show that Fennec Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
March 21, 2024
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
Recap: Fennec Pharmaceuticals Q1 Earnings
May 11, 2023
Via
Benzinga
Earnings Outlook For Fennec Pharmaceuticals
May 10, 2023
Via
Benzinga
Analyst Ratings for Fennec Pharmaceuticals
April 06, 2023
Via
Benzinga
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Highlighted for Surprising Price Action
March 18, 2024
Via
Investor Brand Network
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Making Surprising Moves in Monday Session
November 06, 2023
Via
Investor Brand Network
7 Biotech Stocks Sitting in the Sweet Spot
March 24, 2023
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.
Via
InvestorPlace
US Stocks Open Lower; Dow Dips 250 Points
January 25, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.74% to 33,484.47 while the NASDAQ fell...
Via
Benzinga
Expert Ratings for Fennec Pharmaceuticals
November 22, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals
November 22, 2022
Via
Benzinga
4 Analysts Have This to Say About Fennec Pharmaceuticals
November 22, 2022
Via
Benzinga
Where Fennec Pharmaceuticals Stands With Analysts
November 22, 2022
Via
Benzinga
After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss
September 21, 2022
Via
Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
September 22, 2022
Gainers
Via
Benzinga
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
September 21, 2022
Gainers
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
September 07, 2022
Upgrades
Via
Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
NASDAQ:FENC Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Fennec Pharmaceuticals Inc.
June 01, 2022
San Diego, CA -- (SBWIRE) -- 06/01/2022 -- Certain directors of Fennec Pharmaceuticals Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
U.S. FDA accepts Fennec Pharma's New Drug Application (NDA) Resubmission for PEDMARK
April 27, 2022
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) announced that the U.S.
Via
Benzinga
NASDAQ:FENC Shareholder Notice: Deadline on April 11, 2022 in Lawsuit Against Fennec Pharmaceuticals Inc.
April 11, 2022
San Diego, CA -- (SBWIRE) -- 04/11/2022 -- A deadline is coming up on April 11, 2022 in the lawsuit filed for certain investors of Fennec Pharmaceuticals Inc. (NASDAQ:FENC).
Via
SBWire
FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm
April 11, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.